Author

Paul GINESTE 1

1 Abivax, Paris, France

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire, Bruce E. Sands, Sophie Biguenet, Hartmut Ehrlich, Paul GINESTE, Josianne Nitcheu, William J. Sandborn

ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS

Severine Vermeire, William J. Sandborn, Herbert Tilg, Paul GINESTE, Radoslaw Kempinski, Zsolt Tulassay, Josianne Nitcheu, Sophie Biguenet, Hartmut Ehrlich, Jean-Marc Steens, Bruce E. Sands, Silvio Danese

ORAL ABX464 QD IS SAFE AND EFFICACIOUS DURING 52 WEEKS OPEN LABEL MAINTENANCE FOLLOWING A PLACEBO CONTROLLED INDUCTION STUDY IN ULCERATIVE COLITIS PATIENTS

Severine Vermeire, Xavier Hebuterne, Piotr Napora, Maria Wisniewska Jarosinska, Gyula G. Kiss, Arnaud Bourreille, Przemyslaw Zajac, Josianne Nitcheu, Paul GINESTE, Hartmut Ehrlich, Jean-Marc Steens

PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS

Gert De Hertogh, Jean-Marc Steens, Paul GINESTE, Julien Santo, Severine Vermeire

Item 1 - 4 / 4
1